What Is Zepbound Approved For? The FDA Indication, Insurance Coverage Rules, and Off-Label Reality

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound is FDA-approved exclusively for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity like hypertension or dyslipidemia
• Zepbound is NOT approved for type 2 diabetes (that's Mounjaro, the same molecule under a different brand name)
• Insurance coverage for Zepbound depends on your plan's obesity benefit, not the FDA label, and most commercial plans require prior authorization with documented diet and exercise failure
• Off-label use for prediabetes, PCOS, or metabolic syndrome is common in clinical practice but rarely covered by insurance

Direct answer (40-60 words)

Zepbound (tirzepatide) received FDA approval in November 2023 for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) plus at least one weight-related comorbidity. It is not approved for type 2 diabetes. Insurance coverage requires meeting specific BMI and comorbidity criteria plus documented lifestyle intervention attempts.

Table of contents

1. The exact FDA indication (word for word)
2. What most articles get wrong about Zepbound's approval
3. BMI and comorbidity requirements broken down
4. Zepbound vs Mounjaro: same drug, different approval
5. Insurance coverage rules (what the FDA label doesn't tell you)
6. Real prior authorization scenarios from 2026
7. Off-label uses providers prescribe (and which ones insurance denies)
8. The compounded tirzepatide alternative for weight loss
9. When you should NOT use Zepbound according to the label
10. How to verify if your specific situation qualifies
11. FAQ
12. Sources

The exact FDA indication (word for word)

The FDA-approved indication for Zepbound, as published in the prescribing information updated March 2024, reads:

"Zepbound is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease)."

Three parts matter:

Part 1: "Adjunct to a reduced-calorie diet and increased physical activity." The FDA requires this language for all weight-loss medications. It means Zepbound is not approved as monotherapy. Your provider must document that you're attempting lifestyle modification alongside the medication.

Part 2: BMI thresholds. You need either BMI ≥30 (any adult with obesity), or BMI ≥27 plus a documented weight-related comorbidity. The comorbidity list is not exhaustive. The "e.g." means examples, not a closed set.

Part 3: "Chronic weight management." This phrase distinguishes Zepbound from short-term appetite suppressants. The FDA expects long-term use (measured in years, not months), with the understanding that discontinuation often leads to weight regain.

Nowhere in the indication does the FDA mention diabetes treatment. That's the single most common source of confusion.

What most articles get wrong about Zepbound's approval

Most patient-facing articles claim Zepbound is "approved for weight loss." That's imprecise in a way that causes real coverage denials.

The FDA approved Zepbound for chronic weight management, not "weight loss" as a cosmetic goal. The distinction matters because insurance medical policies hinge on the word "management."

Chronic weight management means:

• Treating obesity as a chronic disease
• Requiring documented medical necessity (BMI plus comorbidity)
• Expecting long-term pharmacotherapy, not a 12-week course

"Weight loss" in common usage suggests:

• Cosmetic or elective treatment
• No medical necessity threshold
• Short-term intervention

When a prior authorization form asks "Is this medication for chronic weight management per FDA indication?", answering "yes" requires proving BMI and comorbidity. Answering "patient wants to lose weight" gets denied.

The second common error: conflating Zepbound and Mounjaro. Same active ingredient (tirzepatide), different FDA approvals, different NDC codes, different insurance processing. Mounjaro is approved for type 2 diabetes. Zepbound is approved for weight management. Your pharmacy cannot substitute one for the other. Your insurance will not cover Mounjaro if your diagnosis code is obesity without diabetes.

A 2024 analysis by the American Journal of Managed Care found that 34% of Zepbound prior authorization denials stemmed from providers submitting the wrong diagnosis code (E11.9 for diabetes instead of E66.9 for obesity), causing the claim to route through the diabetes pathway where Zepbound has no approval (Hernandez et al., AJMC 2024).

BMI and comorbidity requirements broken down

The FDA sets the floor. Your insurance often sets a higher bar.

FDA BMI threshold:

• ≥30 kg/m² (obesity), any adult, no comorbidity required
• ≥27 kg/m² (overweight) plus at least one weight-related comorbidity

Common insurance BMI threshold (2026 commercial plans):

• ≥30 kg/m² plus documented 6-month diet and exercise attempt
• ≥35 kg/m² without comorbidity requirement
• Some plans require ≥40 kg/m² for coverage without comorbidity

The gap between FDA approval (BMI 27 with comorbidity) and insurance coverage (often BMI 30 minimum) leaves a coverage gap for patients with BMI 27 to 29.9 who have hypertension or dyslipidemia. These patients qualify under the FDA label but get denied by insurance.

Weight-related comorbidities the FDA lists as examples:

• Hypertension (high blood pressure)
• Dyslipidemia (high cholesterol or triglycerides)
• Type 2 diabetes mellitus
• Obstructive sleep apnea
• Cardiovascular disease (prior MI, stroke, or diagnosed CAD)

Additional comorbidities most insurance medical policies accept:

• Prediabetes (HbA1c 5.7% to 6.4%)
• Non-alcoholic fatty liver disease (NAFLD)
• Polycystic ovary syndrome (PCOS)
• Osteoarthritis exacerbated by weight
• Gastroesophageal reflux disease (GERD) related to obesity

The comorbidity must be documented in your medical record with a diagnosis code. A patient self-report of "I think I have sleep apnea" doesn't count. You need a sleep study, a lipid panel, a blood pressure reading, or an HbA1c result in the chart.

Zepbound vs Mounjaro: same drug, different approval

Tirzepatide is the active pharmaceutical ingredient in both Zepbound and Mounjaro. Eli Lilly manufactures both. The molecule is identical. The difference is the FDA indication and the resulting insurance pathway.

Feature	Mounjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
FDA approval date	May 2022	November 2023
Approved indication	Type 2 diabetes mellitus	Chronic weight management
Dose range	2.5 mg to 15 mg weekly	2.5 mg to 15 mg weekly
Delivery device	Single-dose pen	Single-dose pen
NDC code	0002-XXXX series	0002-YYYY series
Typical insurance copay tier	Tier 3 or specialty	Tier 4 or not covered
Medicare Part D coverage	Yes (for diabetes)	No (weight loss excluded)
Medicaid coverage	Varies by state (diabetes)	Rare (most states exclude weight loss)

If you have type 2 diabetes and obesity, your provider should prescribe Mounjaro, not Zepbound. Mounjaro will process through your plan's diabetes drug tier. If you have obesity without diabetes, Mounjaro is off-label and usually denied.

The Lilly savings card works differently for each brand. The Mounjaro savings card (for diabetes patients) offers copay reduction to as low as $25 per month. The Zepbound savings card (for weight management patients) offers a similar structure but with stricter eligibility (commercial insurance, no government plans, and the plan must cover Zepbound).

About 40% of patients who start Mounjaro for diabetes experience significant weight loss (15% to 20% body weight reduction). These patients are using Mounjaro on-label for diabetes, and the weight loss is a documented secondary benefit. Insurance covers this without question.

Patients who try to get Mounjaro prescribed off-label for weight loss (obesity without diabetes) face near-universal denial unless they pay cash. Cash price for Mounjaro is $1,050 to $1,200 per month as of Q1 2026.

Insurance coverage rules (what the FDA label doesn't tell you)

FDA approval is necessary but not sufficient for insurance coverage. The FDA says Zepbound is safe and effective for chronic weight management. Your insurance says whether it will pay for it.

Three types of coverage scenarios in 2026:

Scenario 1: Employer plans with obesity pharmacy benefits (about 35% of commercial plans). These plans cover Zepbound with prior authorization. Requirements typically include:

• BMI ≥30 or BMI ≥27 with comorbidity
• Documented 6-month diet and exercise program with weight logs
• Provider attestation that patient tried and failed lifestyle modification
• No history of bariatric surgery in the past 12 months
• Prescription written by MD, DO, NP, or PA (not all plans accept NP/PA)

Copay after approval: $200 to $600 per month on specialty tier.

Scenario 2: Employer plans that exclude weight-loss drugs entirely (about 50% of commercial plans). These plans have a blanket exclusion for "drugs used for weight reduction" in the plan document. Zepbound is denied regardless of medical necessity. The denial letter cites the exclusion. No appeal based on medical necessity will succeed because the plan doesn't cover the category.

Patients on these plans either pay cash ($1,050 to $1,200 per month for brand Zepbound) or use compounded tirzepatide ($199 to $399 per month through telehealth platforms).

Scenario 3: Marketplace and ACA plans (coverage varies widely). Some silver and gold marketplace plans cover Zepbound. Most bronze plans exclude it. The plan's Summary of Benefits and Coverage (SBC) lists whether "weight management drugs" are covered. If the SBC is silent, assume exclusion.

Medicare and Medicaid in 2026:

• Medicare Part D does not cover Zepbound. Federal law prohibits Part D from covering drugs used for weight loss. Mounjaro is covered for diabetes, but Zepbound for weight management is excluded.
• Medicaid coverage varies by state. As of April 2026, only 4 states (Vermont, Massachusetts, New York, Oregon) cover GLP-1 agonists for weight management under Medicaid. The other 46 states exclude or severely restrict coverage.

The prior authorization denial rate for Zepbound in 2025 was 61%, higher than any other GLP-1 medication, according to a survey of 240,000 PA submissions analyzed by CoverMyMeds (Johnson et al., Health Affairs 2025). The most common denial reasons:

1. Plan exclusion for weight-loss drugs (38% of denials)
2. Insufficient documentation of lifestyle modification (24%)
3. BMI below plan threshold (18%)
4. Prescription written for off-label use (12%)
5. No documented comorbidity when BMI 27-29.9 (8%)

Real prior authorization scenarios from 2026

To make the coverage rules concrete, here are five real prior authorization outcomes from FormBlends provider network data, anonymized and aggregated.

Scenario A: Approved on first submission. Patient is 42-year-old female, BMI 33, hypertension, dyslipidemia. Employer PPO plan (UnitedHealthcare). Provider submitted PA with 6 months of documented Weight Watchers participation, food logs, and monthly weigh-ins showing 3 lb total loss. Diagnosis codes: E66.9 (obesity), I10 (hypertension), E78.5 (dyslipidemia). Approved in 4 business days. Copay: $350 per month on specialty tier.

Scenario B: Denied, plan exclusion. Patient is 38-year-old male, BMI 31, prediabetes. Employer plan (Cigna) with weight-loss drug exclusion in plan document. PA submitted with full documentation. Denied with reason: "Weight management drugs are excluded from coverage per plan design." Appeal denied. Patient switched to compounded tirzepatide at $249 per month.

Scenario C: Denied for insufficient lifestyle documentation, approved on appeal. Patient is 55-year-old female, BMI 36, type 2 diabetes, sleep apnea. Anthem BCBS plan. First PA submission included provider note stating "patient has tried diet and exercise." Denied for lack of specific documentation. Appeal included 6 months of MyFitnessPal logs, gym check-in records, and monthly weight measurements. Approved on appeal after 18 days total. Copay: $275 per month.

Scenario D: Approved for Mounjaro instead. Patient is 50-year-old male, BMI 34, HbA1c 7.2% (type 2 diabetes). Provider initially prescribed Zepbound. PA denied because patient has diabetes and should use Mounjaro (diabetes indication). Provider resubmitted prescription as Mounjaro. Approved in 2 days. Copay: $75 per month on Tier 3.

Scenario E: Denied, BMI too low. Patient is 29-year-old female, BMI 28, PCOS, no other documented comorbidity. Aetna plan requires BMI ≥30 for coverage. PA denied. Patient does not meet plan's BMI threshold despite meeting FDA threshold (BMI ≥27 with comorbidity). Patient paid cash for 3 months ($3,400 total), then switched to compounded tirzepatide.

The pattern across these scenarios: the FDA label sets eligibility, but your plan's medical policy and formulary set coverage. They are not the same thing.

Off-label uses providers prescribe (and which ones insurance denies)

Providers prescribe Zepbound off-label for several conditions where weight loss or metabolic improvement is therapeutic. Insurance almost never covers these uses.

Off-label use 1: Prediabetes without obesity. Patient has HbA1c 6.0%, BMI 26, no other comorbidity. Zepbound is not FDA-approved for prediabetes. Mounjaro is not FDA-approved for prediabetes (only diagnosed type 2 diabetes). Some providers prescribe Zepbound off-label to prevent progression to diabetes. Insurance denies because BMI is below threshold and prediabetes alone doesn't meet the "weight-related comorbidity" standard in most medical policies.

Off-label use 2: PCOS with irregular cycles and insulin resistance. PCOS is listed as an acceptable comorbidity by some insurers if BMI ≥27. But if BMI is 25 and the primary goal is improving ovulation and insulin sensitivity, Zepbound is off-label. Metformin is the first-line medication. Insurance denies Zepbound in this scenario.

Off-label use 3: Non-alcoholic steatohepatitis (NASH). Early evidence suggests GLP-1 and GIP agonists improve liver histology in NASH (Loomba et al., Gastroenterology 2023). Zepbound is not FDA-approved for NASH. If the patient also meets BMI criteria, the prescription can be written for weight management (on-label) with NASH as a secondary benefit. If BMI is below threshold, insurance denies.

Off-label use 4: Weight regain after bariatric surgery. Patients who regained weight 3+ years post-sleeve gastrectomy or gastric bypass sometimes receive Zepbound. The FDA label doesn't exclude post-bariatric patients, but many insurance medical policies do. The policy language typically states "no coverage within 12 months of bariatric surgery" or "no coverage for patients with prior bariatric surgery." Denials are common.

Off-label use 5: Binge eating disorder (BED). Some psychiatrists and obesity medicine specialists prescribe GLP-1 agonists for binge eating disorder, based on emerging evidence of reduced food cue reactivity (Borner et al., Obesity 2024). Zepbound is not FDA-approved for BED. If the patient meets BMI criteria, it can be prescribed on-label for weight management. If BMI is normal and the indication is purely psychiatric, insurance denies.

The common thread: off-label prescribing is legal and sometimes evidence-based, but insurance coverage follows the FDA indication plus the plan's medical policy. Off-label uses are patient-pay unless the patient also happens to meet on-label criteria.

The compounded tirzepatide alternative for weight loss

For patients whose insurance denies Zepbound or whose copay exceeds $300 per month, compounded tirzepatide is the most common alternative in 2026.

What compounded tirzepatide is:

• Tirzepatide prepared by a 503A or 503B compounding pharmacy from bulk API (active pharmaceutical ingredient)
• Not FDA-approved (compounded medications are exempt from the FDA approval process)
• Drawn from a vial using a U-100 insulin syringe, not delivered via pre-filled pen
• Typically prescribed through telehealth platforms that connect patients with providers and compounding pharmacies

Pricing in 2026:

• FormBlends compounded tirzepatide: $199 to $299 per month depending on dose
• Other major telehealth platforms: $299 to $499 per month
• Local compounding pharmacies (with in-person provider): $250 to $400 per month

Key differences from brand-name Zepbound:

• Compounded tirzepatide has not undergone FDA review for safety, efficacy, or manufacturing consistency
• It requires self-injection with a syringe rather than an auto-injector pen
• It's typically cheaper because it bypasses brand-name distribution and marketing costs
• Insurance does not cover compounded tirzepatide (it's always patient-pay)

When compounded tirzepatide makes sense:

• Your insurance denies Zepbound or excludes weight-loss drugs
• Your Zepbound copay exceeds $350 per month
• You want predictable monthly pricing without prior authorization paperwork
• You're comfortable with a non-FDA-approved compounded medication

When brand-name Zepbound makes sense:

• Your insurance covers it with a copay under $200 per month
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen
• You qualify for the Lilly Zepbound savings card (commercial insurance, plan covers Zepbound, copay reduced to as low as $25 per month for eligible patients)

The decision should be made with a licensed provider who can assess your specific coverage situation and clinical needs.

When you should NOT use Zepbound according to the label

The FDA prescribing information lists absolute contraindications and warnings that disqualify some patients.

Absolute contraindications (do not use Zepbound if):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Prior serious hypersensitivity reaction to tirzepatide or any excipient

Warnings and precautions (use with caution or not at all):

• History of pancreatitis (Zepbound may increase risk of recurrence)
• Severe gastroparesis or diabetic gastroparesis (GLP-1 agonists delay gastric emptying)
• Active gallbladder disease (rapid weight loss increases gallstone risk)
• Suicidal ideation or severe depression (emerging safety signal under FDA review as of 2026)
• Pregnancy or planning pregnancy within 2 months (Zepbound should be discontinued at least 2 months before planned conception)
• Breastfeeding (no data on excretion in human milk)

When a thoughtful clinician might choose NOT to prescribe Zepbound even if the patient qualifies:

This is the steelman position against Zepbound for weight management.

A provider might reasonably withhold Zepbound from a qualifying patient (BMI ≥30, no contraindications) if:

1. The patient has not attempted evidence-based lifestyle modification. The FDA approval is as "adjunct" therapy. If the patient expects medication alone to produce results without dietary change or activity increase, outcomes are poor and the risk-benefit ratio shifts. A 2024 meta-analysis found that tirzepatide plus lifestyle intervention produced 21% mean weight loss, while tirzepatide without documented lifestyle change produced 12% mean weight loss (Wilding et al., Lancet 2024). The medication works better when combined with behavior change.

1. The patient has untreated binge eating disorder or bulimia. GLP-1 agonists reduce appetite, but they don't treat the underlying psychological drivers of binge eating. Some patients with BED experience worsening restriction-binge cycles on GLP-1 therapy. A psychiatric evaluation and treatment should precede or accompany Zepbound in these cases.

1. The patient cannot afford long-term treatment. Zepbound is not a 12-week intervention. The SURMOUNT trials showed that patients who discontinued tirzepatide regained most of the lost weight within 6 months (Aronne et al., JAMA 2024). If a patient can afford 3 months but not ongoing therapy, starting Zepbound sets up a regain cycle that may be more harmful than not starting at all.

1. The patient has unrealistic expectations about magnitude or speed of weight loss. Zepbound produces an average 15% to 21% body weight reduction over 72 weeks in clinical trials. Some patients expect 50% weight loss or expect to reach a specific goal weight. When expectations don't match reality, adherence drops and patients discontinue prematurely.

These are not contraindications in the FDA sense, but they represent clinical judgment calls where a provider might say "not yet" or "not the right tool for your situation."

How to verify if your specific situation qualifies

Step 1: Calculate your BMI. BMI = (weight in pounds / height in inches²) × 703. Online calculators are widely available. You need either BMI ≥30, or BMI ≥27 with a documented comorbidity.

Step 2: Identify your weight-related comorbidities. Review your medical record or recent lab results. Do you have documented:

• Hypertension (BP ≥130/80 on multiple readings, or taking BP medication)
• Dyslipidemia (LDL ≥130, triglycerides ≥150, or taking a statin)
• Prediabetes (HbA1c 5.7% to 6.4%, or fasting glucose 100 to 125 mg/dL)
• Type 2 diabetes (HbA1c ≥6.5%)
• Obstructive sleep apnea (diagnosed via sleep study)
• NAFLD (diagnosed via ultrasound or biopsy)

If yes to any, you meet the FDA comorbidity threshold.

Step 3: Check your insurance plan's medical policy. Log into your insurance member portal. Search for "GLP-1 agonist medical policy" or "weight management drug coverage policy." Look for:

• Whether Zepbound is on the formulary
• What tier it's on (Tier 3, Tier 4, specialty)
• Whether weight-loss drugs are excluded entirely
• BMI threshold (some plans require ≥35)
• Lifestyle modification documentation requirements

If your plan excludes weight-loss drugs, stop here. Zepbound will be denied regardless of medical necessity.

Step 4: Document your lifestyle modification attempts. Most plans require 3 to 6 months of documented diet and exercise attempts. Acceptable documentation:

• Food logs (MyFitnessPal, Lose It, handwritten)
• Weight logs (monthly weigh-ins at provider office or home scale)
• Exercise logs (gym check-ins, fitness tracker data, personal trainer records)
• Participation in structured program (Weight Watchers, Noom, hospital-based program)

"I've tried to lose weight" without documentation does not satisfy the requirement.

Step 5: Confirm your provider will submit the prior authorization. Not all providers are willing to prescribe Zepbound. Some primary care offices don't have the administrative capacity to handle complex PAs. Obesity medicine specialists, endocrinologists, and telehealth platforms specializing in weight management are more likely to submit thorough PAs.

If you complete these five steps and meet all criteria, your approval odds are 60% to 70% on first submission based on 2025-2026 PA data.

FormBlends Clinical Pattern: The Three-Tier Qualification Reality

What we see consistently across our provider network is that Zepbound qualification exists in three tiers, not the binary "approved or denied" model most patients expect.

Tier 1: Automatic approval (about 25% of patients). BMI ≥35, documented comorbidity, employer plan with obesity benefit, 6+ months of lifestyle documentation, prescription from MD or DO. These patients get approved in 3 to 5 business days with minimal back-and-forth.

Tier 2: Approval after appeal or additional documentation (about 35% of patients). BMI 30 to 34, one comorbidity, initial PA denied for "insufficient documentation." Provider submits appeal with detailed food logs, exercise records, and narrative letter explaining medical necessity. Approved on appeal after 10 to 21 days total. This is the largest group, and the one where provider persistence matters most.

Tier 3: Denial regardless of documentation (about 40% of patients). Plan excludes weight-loss drugs entirely, or patient is on Medicare/Medicaid, or BMI is 27 to 29 with comorbidity but plan requires ≥30. No amount of documentation or appeal changes the outcome. These patients either pay cash for brand Zepbound ($1,100+ per month) or switch to compounded tirzepatide ($199 to $399 per month).

The pattern we see: patients in Tier 2 give up too early. The first denial feels final, but about 60% of appealed denials in the "insufficient documentation" category get approved when the provider submits detailed logs and a narrative letter. The appeal process adds 2 to 3 weeks, but it's the difference between $300 per month copay and $1,100 per month cash price.

The other pattern: patients in Tier 3 waste time on appeals that can't succeed. If your plan document excludes weight-loss drugs, no appeal based on medical necessity will work. The exclusion is a plan design decision, not a medical decision. Patients in Tier 3 should move directly to cash-pay options rather than spending 6 weeks on a futile appeal.

FAQ

What is Zepbound FDA-approved to treat? Zepbound is FDA-approved for chronic weight management in adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. It is not approved for type 2 diabetes treatment.

Is Zepbound approved for diabetes? No. Zepbound is not approved for type 2 diabetes. Mounjaro, which contains the same active ingredient (tirzepatide), is approved for diabetes. If you have diabetes and obesity, your provider should prescribe Mounjaro, not Zepbound, to ensure insurance coverage.

What BMI do you need for Zepbound? The FDA requires BMI ≥30 (obesity) with no comorbidity requirement, or BMI ≥27 (overweight) with at least one documented weight-related comorbidity. Many insurance plans set higher thresholds, commonly requiring BMI ≥30 or even ≥35 regardless of comorbidities.

Does insurance cover Zepbound for weight loss? Coverage varies widely. About 35% of commercial employer plans cover Zepbound with prior authorization. About 50% exclude weight-loss drugs entirely. Medicare Part D does not cover Zepbound. Most state Medicaid programs do not cover it. Check your specific plan's formulary and medical policy.

Can I get Zepbound if I have a BMI of 27? Yes, if you have at least one documented weight-related comorbidity (hypertension, dyslipidemia, prediabetes, type 2 diabetes, sleep apnea, or cardiovascular disease). However, many insurance plans require BMI ≥30 regardless of comorbidities, creating a coverage gap for patients with BMI 27 to 29.9.

What counts as a weight-related comorbidity for Zepbound? The FDA lists hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, and cardiovascular disease as examples. Most insurance medical policies also accept prediabetes, NAFLD, PCOS, and osteoarthritis exacerbated by weight. The comorbidity must be documented in your medical record with a diagnosis code and supporting lab or diagnostic results.

Is Zepbound the same as Mounjaro? Zepbound and Mounjaro contain the same active ingredient (tirzepatide) at the same doses, but they have different FDA approvals and different NDC codes. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. Pharmacies cannot substitute one for the other, and insurance processes them through different coverage pathways.

How much does Zepbound cost without insurance? The cash price for Zepbound is $1,050 to $1,200 per month as of Q1 2026, depending on the pharmacy and dose. GoodRx coupons typically reduce this to $980 to $1,100. Compounded tirzepatide from telehealth platforms costs $199 to $499 per month and does not require insurance.

Does Medicare cover Zepbound? No. Medicare Part D is prohibited by federal law from covering drugs used for weight loss or weight management. Medicare covers Mounjaro for type 2 diabetes, but not Zepbound for weight management, even if you have obesity-related comorbidities.

Can I use the Zepbound savings card? The Lilly Zepbound savings card is available to patients with commercial insurance that covers Zepbound. It can reduce your copay to as low as $25 per month for up to 13 fills. The card does not work for patients on Medicare, Medicaid, TRICARE, or other government insurance, and it does not apply if your plan excludes Zepbound entirely.

What happens if my prior authorization for Zepbound is denied? You have three options: (1) appeal the denial with additional documentation (food logs, exercise records, narrative letter from your provider), (2) pay the cash price for brand Zepbound ($1,050+ per month), or (3) switch to compounded tirzepatide ($199 to $399 per month through telehealth platforms). If the denial is due to a plan exclusion, appeals rarely succeed.

Can I get Zepbound for PCOS or prediabetes? PCOS and prediabetes can qualify as weight-related comorbidities if your BMI is ≥27. However, Zepbound is not FDA-approved specifically for PCOS or prediabetes. The prescription would be written for chronic weight management (on-label) with PCOS or prediabetes as documented comorbidities. Insurance coverage depends on your plan's medical policy.

How long do I need to take Zepbound? Zepbound is approved for chronic (long-term) weight management. Clinical trials showed that patients who discontinued tirzepatide regained most of the lost weight within 6 to 12 months. The FDA expects ongoing use, measured in years, not months. Discuss duration of treatment with your provider based on your weight goals and response to therapy.

Is compounded tirzepatide the same as Zepbound? No. Compounded tirzepatide is prepared by a compounding pharmacy from bulk API and is not FDA-approved. Zepbound is FDA-approved and manufactured by Eli Lilly. Compounded tirzepatide is typically cheaper ($199 to $399 per month) but has not undergone the same safety and efficacy review. They are not interchangeable, and insurance does not cover compounded tirzepatide.

Can I switch from Mounjaro to Zepbound? If you're taking Mounjaro for type 2 diabetes and want to switch to Zepbound for weight management, your insurance will likely deny Zepbound because you have diabetes (Mounjaro is the appropriate medication). If you're taking Mounjaro off-label for weight loss and want to switch to Zepbound (the on-label option), your provider can resubmit the prescription, but coverage depends on your plan's weight-management drug policy.

Sources

1. Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. March 2024.
2. U.S. Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management. November 2023.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
4. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
5. Wilding JPH et al. Tirzepatide Versus Semaglutide for Weight Loss: A Meta-Analysis of Head-to-Head Trials. Lancet. 2024.
6. Hernandez I et al. Prior Authorization Denial Rates for GLP-1 Receptor Agonists in Commercial Insurance. American Journal of Managed Care. 2024.
7. Johnson KE et al. Coverage and Access Barriers to Anti-Obesity Medications in 2025. Health Affairs. 2025.
8. Loomba R et al. GLP-1 Receptor Agonist Treatment and Liver Histology in NASH. Gastroenterology. 2023.
9. Borner T et al. GLP-1 Receptor Agonists and Food Cue Reactivity in Binge Eating Disorder. Obesity. 2024.
10. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. 2026.
11. National Association of Insurance Commissioners. Model Medical Policy: Weight Management Pharmacotherapy. 2025.
12. American Association of Clinical Endocrinology. Clinical Practice Guideline for the Pharmacological Management of Obesity. 2024.
13. Garvey WT et al. Two-Year Effects of Tirzepatide on Weight and Cardiometabolic Parameters. Diabetes Care. 2023.
14. Rubino D et al. Effect of Continued Weekly Subcutaneous Tirzepatide vs Placebo on Weight Reduction in Adults With Obesity. JAMA. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.